Effectiveness of First-Line Treatments in Metastatic Squamous Non-Small-Cell Lung Cancer | Zendy

Benjamin Levy | Zendy; James Signorovitch | Zendy; Hongyan Yang | Zendy; Oscar PattersonLomba | Zendy; Chan Xiang | Zendy; Monika Parisi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effectiveness of First-Line Treatments in Metastatic Squamous Non-Small-Cell Lung Cancer

Author(s) -

Benjamin Levy,

James Signorovitch,

Hongyan Yang,

Oscar PattersonLomba,

Chan Xiang,

Monika Parisi

Publication year - 2019

Publication title -

current oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.053

H-Index - 51

eISSN - 1718-7729

pISSN - 1198-0052

DOI - 10.3747/co.26.4485

Subject(s) - medicine , carboplatin , hazard ratio , gemcitabine , proportional hazards model , lung cancer , oncology , paclitaxel , discontinuation , progression free survival , cancer , chemotherapy , gastroenterology , surgery , confidence interval , cisplatin

Commonly used first-line (1L) chemotherapies for patients with advanced squamous-cell lung cancer (scc) include gemcitabine-platinum (gp), nab-paclitaxel-carboplatin (nabpc), and sb-paclitaxel-carboplatin (sbpc) regimens. However, no head-to-head trials have compared those treatments. In the present study, we compared the efficacy of 1L gp, nabpc, and sbpc in patients with scc and in patients with scc who subsequently received second-line (2L) immunotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research